Results 111 to 120 of about 645 (124)

[Research and International Cooperation for Shortening the Treatment Duration of Tuberculosis]. [PDF]

Jugan Geongang Gwa Jilbyeong
Jeon SM, Kim TH, Lee S, Kim S.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Spectroscopic identification of intermediates and final products of the chiral pool synthesis of sutezolid

Journal of Molecular Structure, 2020
Abstract Sutezolid is a new oxazolidinone derivative currently in clinical trials to determine its safety and efficacy towards highly drug-resistant tuberculosis. The aim of the study was the spectroscopic identification of selected key intermediate products of the chiral pool synthesis of sutezolid: (S1) (4-(2-fluoro-4-nitrophenyl)thiomorpholine ...
Katarzyna Michalska, Kornelia Lewandowska, Mikołaj Mizera, Wojciech Bocian, Barbara Pałys, Judyta Cielecka-Piontek   +5 more
openaire   +1 more source

Characterization of degradation products and process-related impurity of sutezolid by liquid chromatography/electrospray ionization tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis, 2019
Sutezolid was a new oxazolidinone compound used for the treatment of M. tuberculosis. This study describes the separation, characterization and in silico toxicity prediction of three degradation products and one process-related impurity of sutezolid.
Kaijing, Guo, Tingting, Zhang, Yanan, Wang, Bo, Jin, Chen, Ma   +4 more
openaire   +2 more sources

Sutezolid: A promising next generation tuberculosis agent

World Journal of Biology Pharmacy and Health Sciences
Sutezolid (PNU-100480) is an advanced oxazolidinone antibiotic that shows strong effectiveness against Mycobacterium tuberculosis, including those tough multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. It works by blocking bacterial protein synthesis, specifically by attaching to the 23S rRNA of the 50S ribosomal subunit, which ...
Kiran, Garlapati Usha, kumar, Loya Pavan, Mahesh, Maareedu, manikanta, Kankanala Uma Satya, Nehemiah, Gollamudi, kumar, Guntru Pavan   +5 more
openaire   +1 more source

Enantioselective recognition of sutezolid by cyclodextrin modified non-aqueous capillary electrophoresis and explanation of complex formation by means of infrared spectroscopy, NMR and molecular modelling

Journal of Pharmaceutical and Biomedical Analysis, 2019
A method for the enantioseparation of sutezolid, the next analogue after linezolid and tedizolid, belonging to the truly new class of antibacterial agents, the oxazolidinones, was developed based on non-aqueous capillary electrophoresis (NACE), using a single isomer of cyclodextrins as a chiral pseudophase.
Katarzyna Michalska, Wojciech Bocian, Elżbieta Bednarek, Barbara Pałys, Judyta Cielecka-Piontek   +4 more
openaire   +2 more sources

The synthesis of sutezolid and eperezolid using proline catalyzed α-aminoxylation of an aldehyde

Journal of Chemical Sciences, 2022
Pankaj R Chaudhari, Nandu B Bhise, Girij P Singh, Varadaraj Bhat, Gautham G Shenoy   +4 more
openaire   +1 more source

Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tuberculosis.

Antimicrobial agents and chemotherapy, 2015
Sutezolid (PNU-100480 [U-480]) is an oxazolidinone antimicrobial being developed for the treatment of tuberculosis. An active sulfoxide metabolite (PNU-101603 [U-603]), which reaches concentrations in plasma several times those of the parent, has been reported to drive the killing of extracellular Mycobacterium tuberculosis by sutezolid in hollow-fiber
Zhu, Tong, Friedrich, Sven O., Diacon, Andreas, Wallis, Robert S.   +3 more
openaire   +2 more sources